06-18-2018 01:04 PM CET - Health & Medicine

Global Fibrosarcoma Market To Reach Value Nearly US$ 442.2 Mn Revenues by 2026

Press release from: Fact.MR
Undertaking radiotherapy for the treatment of malignant tumor has led to prevalence of fibrosarcoma among cancer patients. Fibrosarcoma is a rare malignant tumor that is generally treated by conducting radiation treatments and chemotherapy. As there are very few treatment procedures for fibrosarcoma, research and healthcare institutions are investing in research and development to develop effective treatment techniques. In addition, leading research institutes are focusing on developing targeted therapies that targets on eliminating the tumor.

Request For Sample Report @ www.factmr.com/connectus/sample?flag=S&rep_id=353

Researchers are also focusing on developing anti-angiogenesis agents to develop an effective treatment of fibrosarcoma. As fibrosarcoma is mainly prevalent among male population, research institutions are concentrating on developing medications that are specific to the treatment needs of adult men.

Over US$ 400 Mn Opportunity in Global Fibrosarcoma Market

According to Fact.MR, the global fibrosarcoma market is expected to reach a value of more than US$ 400 Mn by 2026-end. Prevalence of fibrosarcoma is mainly associated with genetic mutations. Conducting treatment procedures such as radiotherapy has also led to growing prevalence of fibrosarcoma globally. Fibrosarcoma is mainly prevalent among the male population aged between 30 to 40 years. As researchers and healthcare professionals have not been able to identify the cause of fibrosarcoma, there are very few techniques for treating this disease. Fibrosarcoma is mainly treated by chemotherapy and various radiation treatment techniques. However, these treatment procedures have not been an effective option. In order to develop effective treatment techniques, the research and healthcare institutions are increasingly investing in research and development activities. Researchers are focusing on developing targeted treatment techniques that exploit the biological characteristic of the cancer cell and eliminate the tumor. Conducting chemotherapy treatment procedure include intake of combination of various medications. As some of the sarcomas are sensitive to chemotherapy procedures, the pharmaceutical and research institutions are concentrating on developing effective medications with low side effect.

Growing need to treat fibrosarcoma has led the healthcare professionals to conduct chemotherapy as compared to other treatment techniques. Chemotherapy is mainly conducted in cases when the cancer is large and has not spread in other parts of the body. In terms of revenue, chemotherapy is expected to represent the highest growth in the global market by 2026-end. Government in various countries are increasingly investing in the healthcare industry for development of better infrastructure with effective facilities has enabled healthcare institutions to treat various diseases. Growing need to treat fibrosarcoma in various hospitals is likely to impact growth of the global market. Hospitals is expected to witness significant revenue growth in the global market by 2017-end.

Sales of medications and medical devices for the treatment of fibrosarcoma will continue to remain high through hospital pharmacies. In addition, hospital pharmacies are emerging as the major distributor channel for medications used for the treatment of fibrosarcoma. In terms of revenue, the hospital pharmacies will continue to generate significant revenue in the global market by 2026-end.

Browse Full Report with TOC @ www.factmr.com/report/353/fibrosarcoma-market

Hospital Pharmacy to Emerge as One of the Largest Distributors

Hospital pharmacy is likely to be one of the largest distribution channels in the global fibrosarcoma market during 2017-2026. Hospital pharmacy is projected to bring in nearly US$ 200 million revenue towards 2026 end. Hospital pharmacy in many countries is emerging as the biggest distributors of the drugs used in treating cancer. Moreover, availability of various drugs and government support are also resulting in the growth of the hospital pharmacy as a distribution channel. 

Competition Tracking

The report offers information on the key companies that are likely to play an active role in the expansion of global fibrosarcoma market through 2026, which include Cadila Pharmaceuticals Limited, Celon Laboratories Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Limited, Sun Pharmaceutical Industries Limited, Novartis AG, Baxter International Inc., Eli Lilly and Company, Pfizer Inc., and Johnson & Johnson.

Buy Now @ www.factmr.com/checkout/353/S

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Healthcare Market Research Reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us                                                                                                  
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow us on LinkedIn: www.linkedin.com/company/factmr/

This release was published on openPR.
News-ID: 1086221 • Views: 94
More releasesMore releases

You can edit or delete your press release here: